Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck, Archemix link for aptamers

January 22, 2007 | A version of this story appeared in Volume 85, Issue 4

Germany's Merck has signed a multiyear agreement with Archemix that focuses on the discovery of aptamer-based drugs to treat cancer. Cambridge, Mass.-based Archemix will receive an up-front payment and research funding of as much as $10 million. It could also receive milestone and royalty payments. Archemix says it has signed four aptamer partnerships over the past six months, including one recently with Pfizer (C&EN, Jan. 15, page 34)

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.